Related references
Note: Only part of the references are listed.The rat ErbB2 tyrosine kinase receptor produced in plants is immunogenic in mice and confers protective immunity against ErbB2(+) mammary cancer
Slavica Matic et al.
PLANT BIOTECHNOLOGY JOURNAL (2016)
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial
Elisabeth Quoix et al.
LANCET ONCOLOGY (2016)
Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study
Katy J. McCann et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
Cornelia L. Trimble et al.
LANCET (2015)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular Lymphoma
Daniel Tuse et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp
Xiangguo Qiu et al.
NATURE (2014)
Comparison of prophylactic and therapeutic immunisation with an ErbB-2 (HER2) fusion protein and immunoglobulin V-gene repertoire analysis in a transgenic mouse model of spontaneous breast cancer
Arunima Mukhopadhyay et al.
VACCINE (2014)
Manufacturing Economics of Plant-Made Biologics: Case Studies in Therapeutic and Industrial Enzymesy
Daniel Tuse et al.
BIOMED RESEARCH INTERNATIONAL (2014)
DNA fusion vaccine designs to induce tumor-lytic CD8+T-cell attack via the immunodominant cysteine-containing epitope of NY-ESO 1
Juan Campos-Perez et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Sandra M. Swain et al.
ONCOLOGIST (2013)
DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8+ T-cell responses and increases PSA doubling time
Lindsey Chudley et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
Erika Hamilton et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells
Xiu-Rong Ren et al.
BREAST CANCER RESEARCH (2012)
High-affinity memory B cells induced by conjugate vaccines against weak tumor antigens are vulnerable to nonconjugated antigen
Natalia Savelyeva et al.
BLOOD (2011)
Molecular mechanisms of T-cell tolerance
Roza I. Nurieva et al.
IMMUNOLOGICAL REVIEWS (2011)
Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells
Megan K. L. MacLeod et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Anti-HER2 vaccines: new prospects for breast cancer therapy
Maha Zohra Ladjemi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Understanding and activating immunity against human cancer
Freda K. Stevenson et al.
CURRENT OPINION IN IMMUNOLOGY (2010)
Bystander stimulation of activated CD4+ T cells of unrelated specificity following a booster vaccination with tetanus toxoid
Gianfranco Di Genova et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Erbb2 DNA Vaccine Combined with Regulatory T Cell Deletion Enhances Antibody Response and Reveals Latent Low-Avidity T Cells: Potential and Limits of Its Therapeutic Efficacy
Simona Rolla et al.
JOURNAL OF IMMUNOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years
Mark H. Einstein et al.
HUMAN VACCINES (2009)
Cytokine-secreting follicular T cells shape the antibody repertoire
R. Lee Reinhardt et al.
NATURE IMMUNOLOGY (2009)
Systemic spread is an early step in breast cancer
Yves Huesemann et al.
CANCER CELL (2008)
Primary CD8+ T-cell response to soluble ovalbumin is improved by chloroquine treatment in vivo
Bruno Garulli et al.
CLINICAL AND VACCINE IMMUNOLOGY (2008)
Protective immunity against neu-positive carcinomas elicited by electroporation of plasmids encoding decreasing fragments of rat neu extracellular domain
Simona Rolla et al.
HUMAN GENE THERAPY (2008)
Cardiotoxicity associated with the use of trastuzumab in breast cancer patients
Patrick J. Perik et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure:: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity
M. A. de Korte et al.
EUROPEAN JOURNAL OF CANCER (2007)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Imaging of germinal center selection events during affinity maturation
Christopher D. C. Allen et al.
SCIENCE (2007)
Viral vectors for the expression of proteins in plants
Yuri Gleba et al.
CURRENT OPINION IN BIOTECHNOLOGY (2007)
Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help
N Savelyeva et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Magnifection - a new platform for expressing recombinant vaccines in plants
Y Gleba et al.
VACCINE (2005)
Electroporated DNA vaccine clears away multifocal mammary carcinomas in Her-2/neu transgenic mice
E Quaglino et al.
CANCER RESEARCH (2004)
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
MC Franklin et al.
CANCER CELL (2004)
Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions
E Quaglino et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-γ and B cell dependent
P Nanni et al.
JOURNAL OF IMMUNOLOGY (2004)
DNA vaccines to attack cancer
FK Stevenson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Extrafollicular antibody responses
ICM MacLennan et al.
IMMUNOLOGICAL REVIEWS (2003)
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
HS Cho et al.
NATURE (2003)
Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2
MP Piechocki et al.
JOURNAL OF IMMUNOLOGY (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
DNA vaccination against rat Her-2/neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice
S Rovero et al.
JOURNAL OF IMMUNOLOGY (2000)